La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

CardieX Gestione

Gestione criteri di controllo 2/4

CardieX's Il CEO è Craig Cooper, nominato in Dec2017, e ha un mandato di 6.67 anni. la retribuzione annua totale è A$ 1.50M, composta da 42.2% di stipendio e 57.8% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 2.21% delle azioni della società, per un valore di A$ 370.18K. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 2.8 anni e 6 anni.

Informazioni chiave

Craig Cooper

Amministratore delegato

AU$1.5m

Compenso totale

Percentuale dello stipendio del CEO	42.2%
Mandato del CEO	6.7yrs
Proprietà del CEO	2.2%
Durata media del management	2.8yrs
Durata media del Consiglio di amministrazione	6yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Craig Cooper rispetto agli utili di CardieX?
Data	Compenso totale	Stipendio	Guadagni aziendali
Dec 31 2023	n/a	n/a	-AU$9m
Sep 30 2023	n/a	n/a	-AU$14m
Jun 30 2023	AU$1m	AU$631k	-AU$19m
Mar 31 2023	n/a	n/a	-AU$16m
Dec 31 2022	n/a	n/a	-AU$14m
Sep 30 2022	n/a	n/a	-AU$13m
Jun 30 2022	AU$1m	AU$608k	-AU$12m
Mar 31 2022	n/a	n/a	-AU$11m
Dec 31 2021	n/a	n/a	-AU$10m
Sep 30 2021	n/a	n/a	-AU$7m
Jun 30 2021	AU$1m	AU$529k	-AU$5m
Mar 31 2021	n/a	n/a	-AU$4m
Dec 31 2020	n/a	n/a	-AU$3m
Sep 30 2020	n/a	n/a	-AU$3m
Jun 30 2020	AU$911k	AU$447k	-AU$3m
Mar 31 2020	n/a	n/a	-AU$3m
Dec 31 2019	n/a	n/a	-AU$4m
Sep 30 2019	n/a	n/a	-AU$3m
Jun 30 2019	AU$851k	AU$419k	-AU$3m
Mar 31 2019	n/a	n/a	-AU$3m
Dec 31 2018	n/a	n/a	-AU$3m
Sep 30 2018	n/a	n/a	-AU$3m
Jun 30 2018	AU$392k	AU$226k	-AU$3m

Compensazione vs Mercato: La retribuzione totale di Craig ($USD 1.00M ) è superiore alla media delle aziende di dimensioni simili nel mercato Australian ($USD 299.11K ).

Compensazione vs guadagni: La retribuzione di Craig è aumentata nonostante l'azienda non sia redditizia.

AMMINISTRATORE DELEGATO

Craig Cooper (60 yo)

6.7yrs

Mandato

AU$1,495,699

Compensazione

Mr. Craig R. Cooper, BEc., LLB (Hons), is the Co-Owner at C2 Ventures Pty Ltd. He is Co-Founder, Group CEO, MD & Executive Director of CardieX Limited. He was Co-Founder, CEO, MD & Executive Director of Ca...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Niall Charles Cairns	Co-Founder & Executive Chairman	6.7yrs	AU$1.02m	0.66% A$ 110.4k
Craig Cooper	Co-Founder	6.7yrs	AU$1.50m	2.21% A$ 370.2k
Ahmad Qasem	Chief Science & Research Officer	no data	AU$240.19k	0.0084% A$ 1.4k
Steven Kesten	Chief Medical Officer	3.7yrs	AU$240.53k	0% A$ 0
Mark Gorelick	Chief Product Officer	3.7yrs	AU$395.47k	0.038% A$ 6.3k
Catherine Liao	Chief Strategy Officer	1.9yrs	AU$385.31k	0% A$ 0
Douglas Kurschinski	Executive VP & Head of Global Sales for AtCor Medical Division	no data	AU$360.84k	Nessun dato
Sanjeev Bhavnani	Chief Clinical Officer	less than a year	Nessun dato	Nessun dato
Louisa Ho	Company Secretary	1.2yrs	Nessun dato	Nessun dato

2.8yrs

Durata media

60yo

Età media

Gestione esperta: Il team dirigenziale di CDX è considerato esperto (durata media dell'incarico 2.8 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Niall Charles Cairns	Co-Founder & Executive Chairman	6.7yrs	AU$1.02m	0.66% A$ 110.4k
Craig Cooper	Co-Founder	6.7yrs	AU$1.50m	2.21% A$ 370.2k
Randall Nelson	Independent Non-Executive Director	8.8yrs	AU$194.65k	0.0052% A$ 877.0
Harry Kim	Special Advisor	5.4yrs	Nessun dato	Nessun dato
Alberto Avolio	Member of Medical Advisory Board	no data	Nessun dato	Nessun dato
John Cockcroft	Member of Medical Advisory Board	2.2yrs	Nessun dato	Nessun dato
Charlie Taylor	Independent Non-Executive Director	less than a year	Nessun dato	Nessun dato

6.0yrs

Durata media

60yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CDX sono considerati esperti (durata media dell'incarico 6 anni).

CardieX Gestione

Gestione criteri di controllo 2/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

Less than half of directors are independent

Recent updates

New major risk - Market cap size

Less than half of directors are independent

CardieX Limited Appoints Charlie Taylor as an Independent Non-Executive Director, Effective 1 March 2024

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4 million.

CardieX Limited has filed a Follow-on Equity Offering in the amount of AUD 7.62 million.

CardieX Limited, Annual General Meeting, Nov 30, 2023

CardieX Limited Announces Resignation of Lesa Musatto as Independent Non-Executive Director

Full year 2023 earnings released: AU$0.15 loss per share (vs AU$0.12 loss in FY 2022)

New minor risk - Financial data availability

CardieX Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

CardieX Limited announced that it expects to receive AUD 2.3 million in funding

First half 2023 earnings released: AU$0.072 loss per share (vs AU$0.053 loss in 1H 2022)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.044413 million.

CardieX Limited Appoints Reid Yeoman as the Group's New Us Based Chief Financial Officer

CardieX Limited (ASX:CDX) acquired All the Assets of Blumio, Inc.

Less than half of directors are independent

CardieX Limited, Annual General Meeting, Nov 30, 2022

CardieX Limited Auditor Raises 'Going Concern' Doubt

Full year 2022 earnings released: AU$0.12 loss per share (vs AU$0.059 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 1 million.

Full year 2022 earnings released: AU$0.11 loss per share (vs AU$0.064 loss in FY 2021)

CardieX Limited has completed a Follow-on Equity Offering in the amount of AUD 4.330001 million.

CardieX Limited Announces FDA 510(K) Submission for Conneqt Pulse Dual Blood Pressure and Arterial Health Monitor

FDA Update for CONNEQT Companion App of Cardiex Limited

CardieX Limited Announces Appointment of Lesa Musatto as an Independent, Non-Executive Director

Less than half of directors are independent

CardieX Submits FDA Application for its CONNEQT App

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Global Health Technology Company CardieX and Mobvoi Launch a Revolutionary Heart Health Monitoring Smartwatch for Consumers

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

Full year 2021 earnings released: AU$0.006 loss per share (vs AU$0.005 loss in FY 2020)

CardieX Launches CONNEQT™

What Can We Learn About CardieX's (ASX:CDX) CEO Compensation?

Shareholders Are Thrilled That The CardieX (ASX:CDX) Share Price Increased 169%

CardieX Limited Announces New Devices on Track for Launch in 2021

CardieX Limited Announces Executive Appointments

Have Insiders Been Buying CardieX Limited (ASX:CDX) Shares?

CardieX Limited, Annual General Meeting, Dec 11, 2020

CardieX Limited Limited Announces Commercial Partnership Agreement with Mobvoi for New Health Smartwatch

Full year earnings released - AU$0.0046 loss per share

Full year earnings released - AU$0.0046 loss per share

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media

Membri del Consiglio di amministrazione

Durata media

Età media